On January 12, 2022 Abintus Bio, Inc. (Abintus), a company pioneering first-in-class, off-the-shelf medicines that reprogram cells directly in vivo, reported its participation in the 40th Annual J.P. Morgan Healthcare Conference (Press release, Abintus Bio, JAN 12, 2022, View Source [SID1234598638]).Nicholas Boyle, Ph.D., Co-Founder, President and Chief Executive Officer, will present an overview of the company on January 13, 2022, at 10:00 am ET, and the presentation will be available to registered conference attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, Abintus will be participating in a panel discussion organized by The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP) titled "Expanding the Possible with Next-Generation Cell Therapies." The event will be held virtually on January 21, 2022, at 12:00 pm ET.